
Results
225
Mid-Large Cap Stocks
225 companies
Bristol-Myers Squibb
Market Cap: US$113.4b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$55.00
7D
-0.5%
1Y
17.8%
Johnson & Johnson
Market Cap: US$575.5b
Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
JNJ
US$241.00
7D
2.9%
1Y
58.3%
Zoetis
Market Cap: US$32.2b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$78.17
7D
1.2%
1Y
-50.3%
Amgen
Market Cap: US$189.7b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGN
US$351.43
7D
4.1%
1Y
25.9%
Gilead Sciences
Market Cap: US$155.4b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$125.16
7D
1.1%
1Y
16.3%
AbbVie
Market Cap: US$414.8b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$234.89
7D
6.2%
1Y
26.7%
Merck
Market Cap: US$295.4b
Operates as a healthcare company worldwide.
MRK
US$120.60
7D
4.5%
1Y
51.4%
Phibro Animal Health
Market Cap: US$1.3b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$31.36
7D
-1.5%
1Y
24.8%
Agilent Technologies
Market Cap: US$35.8b
Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
A
US$131.63
7D
5.9%
1Y
11.0%
Pfizer
Market Cap: US$140.9b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
PFE
US$24.04
7D
-7.3%
1Y
-0.9%
Perrigo
Market Cap: US$1.3b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$9.76
7D
-3.9%
1Y
-63.3%
Danaher
Market Cap: US$126.7b
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
DHR
US$188.87
7D
6.3%
1Y
-6.0%
Viatris
Market Cap: US$18.6b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.93
7D
3.6%
1Y
74.7%
Royalty Pharma
Market Cap: US$31.9b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$54.28
7D
1.1%
1Y
51.2%
Qiagen
Market Cap: US$7.7b
Provides sample to insight solutions that transform biological samples into molecular insights worldwide.
QGEN
US$38.73
7D
5.9%
1Y
-22.5%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$58.48
7D
3.0%
1Y
151.6%
Hisamitsu Pharmaceutical
Market Cap: US$8.2b
Manufactures and sells pharmaceuticals in Japan.
HTSU.Y
US$4.55
7D
0%
1Y
n/a
Centessa Pharmaceuticals
Market Cap: US$6.3b
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
CNTA
US$40.50
7D
1.2%
1Y
210.6%
Dianthus Therapeutics
Market Cap: US$5.0b
A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
DNTH
US$90.80
7D
10.1%
1Y
400.8%
Kodiak Sciences
Market Cap: US$2.2b
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
KOD
US$36.00
7D
-0.4%
1Y
852.4%
Nurix Therapeutics
Market Cap: US$2.0b
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
NRIX
US$19.30
7D
10.0%
1Y
63.0%
MeiraGTx Holdings
Market Cap: US$1.1b
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$11.60
7D
2.5%
1Y
73.9%
Medpace Holdings
Market Cap: US$14.6b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$512.79
7D
11.4%
1Y
67.1%
ADMA Biologics
Market Cap: US$2.0b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$8.70
7D
4.7%
1Y
-52.7%
Trulieve Cannabis
Market Cap: US$1.6b
Operates as a cannabis retailer in the United States.
TRLV
US$8.50
7D
-10.1%
1Y
133.5%
ARS Pharmaceuticals
Market Cap: US$1.0b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$10.54
7D
9.2%
1Y
-41.7%
Adaptive Biotechnologies
Market Cap: US$3.1b
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
ADPT
US$19.34
7D
10.3%
1Y
59.0%
Capricor Therapeutics
Market Cap: US$1.7b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$29.51
7D
4.0%
1Y
189.9%
Vaxcyte
Market Cap: US$7.8b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$53.87
7D
4.7%
1Y
63.8%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$509.76
7D
0.8%
1Y
70.2%
Trevi Therapeutics
Market Cap: US$2.5b
A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$17.52
7D
1.8%
1Y
209.5%
Intellia Therapeutics
Market Cap: US$2.2b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$15.50
7D
-1.1%
1Y
61.3%
Revolution Medicines
Market Cap: US$36.1b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$169.77
7D
4.2%
1Y
353.0%
Organon
Market Cap: US$3.5b
Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$13.48
7D
0.4%
1Y
34.8%
Illumina
Market Cap: US$26.5b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$175.09
7D
8.1%
1Y
85.9%
ACADIA Pharmaceuticals
Market Cap: US$3.9b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$23.36
7D
8.1%
1Y
3.8%